Content area
Abstract
Objective: This ELECT prospective analysis examined lanreotide depot/autogel for carcinoid syndrome (CS) symptom control in patients with neuroendocrine tumors (NETs) who were responsive to prior octreotide (prior octreotide group) compared with patients who were narve to prior somatostatin analogue treatment (de novo group).
Details
Title
LANREOTIDE THERAPY IN CARCINOID SYNDROME: PROSPECTIVE ANALYSIS OF PATIENT-REPORTED SYMPTOMS IN PATIENTS RESPONSIVE TO PRIOR OCTREOTIDE THERAPY AND PATIENTS NAÏVE TO SOMATOSTATIN ANALOGUE THERAPY IN THE ELECT PHASE 3 STUDY
Author
Fisher, George A, Jr, MD 1 ; Wolin, Edward M, MD 2 ; Liyanage, Nilani, MSc 3 ; Lowenthal, Susan Pitman, MD 4 ; Mirakhur, Beloo, MD 4 ; Pommier, Rodney F, MD; Shaheen, Montaser, MD; Vinik, Aaron I, MD
1 Department of Medical Oncology, Stanford University School of Medicine, Stanford, California
2 Department of Medical Oncology, Montefiore Einstein Center for Cancer Care, Bronx, New York
3 Ipsen, Les Ulis, France
4 Department of Medical Affairs, Ipsen, Basking Ridge, New Jersey
1 Department of Medical Oncology, Stanford University School of Medicine, Stanford, California
2 Department of Medical Oncology, Montefiore Einstein Center for Cancer Care, Bronx, New York
3 Ipsen, Les Ulis, France
4 Department of Medical Affairs, Ipsen, Basking Ridge, New Jersey
Pages
243-255
Section
Original Article
Publication year
2018
Publication date
Mar 2018
ISSN
1530891X
e-ISSN
19342403
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2015781697
Copyright
Copyright Allen Press Publishing Services Mar 2018